← Back to Home

No Dedicated Drugs for Alzheimer’s Disease Psychosis; Acadia Candidate Receives FDA Fast Track Designation

Remlifanserin targets hallucinations and delusions, with Phase 2 results expected this fall and Phase 3 enrollment already launched ahead of schedule; as the regulatory process accelerates, evidence of efficacy and safety still awaits answers from publicly available data.

By SURL BioNews

Alzheimer’s disease causes more than memory loss. When hallucinations and delusions emerge, patients may become fearful of familiar people and surroundings, sharply increasing the burden on caregivers. Yet there are currently no drugs specifically approved in the United States to treat psychotic symptoms associated with Alzheimer’s disease. This treatment gap is the backdrop to the U.S. Food and Drug Administration (FDA) granting Fast Track designation to Acadia Pharmaceuticals’ candidate remlifanserin.

The designation covers hallucinations and delusions associated with Alzheimer’s disease psychosis. Fast Track is intended to enable closer development communication with the FDA and expedite the review of drugs that treat serious conditions and may address unmet needs. It is not marketing authorization, nor does it mean that the regulator has confirmed the drug’s efficacy or safety.

Remlifanserin, also known as ACP-204, is a highly selective serotonin 5-HT2A receptor inverse agonist. Acadia’s pharmacological rationale is that modulating this signaling pathway, which is associated with perception and neuronal excitability, may reduce hallucinations and delusions without directly blocking dopamine D2 receptors, potentially avoiding some of the tolerability issues commonly seen with atypical antipsychotics. However, these potential advantages currently remain primarily a mechanistic hypothesis and a development claim by the company and must be validated through comparative clinical evidence.

A milestone that will determine the program’s direction is approaching quickly. Acadia said enrollment has been completed for the Phase 2 portion of the RADIANT program, with preliminary topline results expected to be announced between September and October 2026. The company has adopted a design intended to transition into late-stage development, and screening and enrollment for the Phase 3 study have also begun, indicating that it is advancing on a tighter timeline rather than waiting for the complete Phase 2 data before starting the next stage.

This parallel arrangement may shorten the development gap, but it also makes the forthcoming Phase 2 results more critical: if the magnitude of efficacy, statistical reliability, or safety falls short of expectations, subsequent trials may still need to be adjusted. The announcement did not provide the number of participants, primary endpoints, control method, or adverse-event data, so it is not yet possible to determine whether the drug can reduce symptoms while also addressing the risks of falls, sedation, or cardiovascular events to which older patients with dementia are particularly vulnerable.

Fast Track opens a smoother regulatory pathway for remlifanserin, not a shortcut to efficacy. The upcoming Phase 2 readout will provide the first clearer test of whether selective 5-HT2A modulation can translate into clinically meaningful improvement and will also influence whether the Phase 3 program already underway maintains its current pace and design.

References

  1. Acadia Pharmaceuticals
  2. RTTNews
  3. BioSpace